Roivant Sciences' ulcerative colitis therapy, RVT-3101, shows promising results in Phase 2b trial, attracting interest from major pharmaceutical companies. The company ended the fiscal year with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results